Medigene sells partial stake in Immunocore
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focussing on the development of…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focussing on the development of…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard) announced today that the Company's CFO, Peter Llewellyn-Davies, after more…
4SC AG (4SC, FWB Prime Standard: VSC) has received an "investigational new drug" (IND) approval from the US Food and Dru…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Early results from an ongoing Phase I/II IIT and a Compassionate Use Programme presented on two posters by academic part…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs mainly foc…
. - Shareholders approve all resolutions with a high majority - Creation of new Authorized Capital resolved Medigene AG…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various do…